This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Top Stock Reports for Eli Lilly, Union Pacific & Freeport-McMoRan
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Union Pacific Corporation (UNP), and Freeport-McMoRan Inc. (FCX).
Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.
Boston Scientific (BSX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.27% and 0.91%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Feb 2: BSX, TMO & More
by Riya Anand
Medical Products companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BSX, TMO, HOLX and MCK are poised ahead of their earnings releases.
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Boston Scientific's (BSX) Q4 Earnings?
by Zacks Equity Research
On a geographic basis, every Boston Scientific (BSX) market in fourth-quarter 2021 is expected to have registered broad-based growth compared with the dull fourth-quarter 2020 numbers.
Boston Scientific (BSX) Hit by Procedure Deferrals Amid COVID
by Zacks Equity Research
Although Boston Scientific (BSX) reports margin expansion on a year-over-year basis, the decline in R&D expenses is concerning.
4 Internet of Medical Things (IoMT) Stocks to Buy for 2022
by Riya Anand
Stocks like Boston Scientific (BSX), Medtronic (MDT), DexCom (DXCM) and Syneos Health (SYNH) are evolving rapidly in the field of IoMT.
The Zacks Analyst Blog Highlights: JPMorgan, Walmart, PayPal, Equinix and Boston Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Walmart, PayPal, Equinix and Boston Scientific
Top Analyst Reports for JPMorgan, Walmart & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Walmart Inc. (WMT), and PayPal Holdings, Inc. (PYPL).
Top Analyst Reports for JPMorgan, Walmart & PayPal
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Walmart Inc. (WMT), and PayPal Holdings, Inc. (PYPL).
Boston Scientific (BSX) New Buyouts Aid Amid COVID Resurgence
by Zacks Equity Research
Boston Scientific's (BSX) new acquisitions like Preventice, Farapulse and Lumenis Surgical, which closed in March, August and September of 2021, respectively, are contributing to its inorganic growth.
Here's Why You Should Retain Boston Scientific (BSX) for Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.
The Zacks Analyst Blog Highlights: Alibaba, Abbott Laboratories, T-Mobile, Anheuser-Busch and Boston Scientific Corp
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alibaba, Abbott Laboratories, T-Mobile, Anheuser-Busch and Boston Scientific Corp
Top Analyst Reports for Alibaba, Abbott & T-Mobile US
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Limited (BABA), Abbott Laboratories (ABT), and T-Mobile US, Inc. (TMUS).
QIPT vs. BSX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
QIPT vs. BSX: Which Stock Is the Better Value Option?
4 Medical Products Stocks Poised to Beat This Earnings Season
by Urmimala Biswas
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
Boston Scientific (BSX) Q3 Earnings Beat Estimates
by Zacks Equity Research
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.50% and -1.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More
by Urmimala Biswas
With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.
Boston Scientific (BSX) Product Launches to Drive Q3 Earnings
by Zacks Equity Research
Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
by Zacks Equity Research
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
by Zacks Equity Research
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
by Zacks Equity Research
The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.